Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells

Prostate

Volumn 67, Issue 15, 2007, Pages 1699-1717

  Leroux, M E ^a   Auzenne, E ^a   Evans, R ^a   Hail Jr , N ^b   Spohn, W ^a   Ghosh, S C ^a   Farquhar, D ^a   McDonnell, T ^a   Klostergaard, J ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE   (United States)

Author keywords

BCL 2 independent apoptosis; Human prostatic adenocarcinoma; Sphingolipids and the sphingosine kinase inhibitor

Indexed keywords

ANNEXIN; CERAMIDE; CYTOCHROME C; DNA FRAGMENT; N,N DIMETHYLSPHINGOSINE; PROTEIN BCL 2; PROTEIN BNIP3; REACTIVE OXYGEN METABOLITE; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE INHIBITOR; SPHINGOSINE KINASE INHIBITOR II; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SPHINGOSINE; THIAZOLES;

EID: 35648995431     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20645     Document Type: Article

References (86)

1. Catz SD, Johnson JL. BCL-2 in prostate cancer: A minireview. Apoptosis 2003;8(1):29-37.
2. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940-6944.
3. Rothermund CA, Kondrikov D, Lin MF, Vishwanatha JK. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer Prostatic Dis 2002;5(3):236-245.
4. Rothermund CA, Gopalakrishnan VK, Vishwanatha JK. Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer. Prostate Cancer Prostatic Dis 2004;7(2):158-164.
5. Petrylak DP. Future directions in the treatment of and rogen-independent prostate cancer. Urology 2005;65 (6 Suppl):8-12.
6. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004;128(1):39-43.
7. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41(6):858-887.
8. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005;113(4):619-628.
9. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644(2-3):229-249.
10. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60(21):6101-6110.
11. Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S, Dent P, Reed JC, Fisher PB. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: Overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the anti-apoptotic proteins bcl-x(L): Or bcl-2. Oncogene 2005.
12. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005;115(10):2648-2655.
13. Sakakura C, Sweeney EA, Shirahama T, Hakomori S, Igarashi Y. Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation. FEBS Lett 1996;379(2):177-180.
14. Shirahama T, Sakakura C, Sweeney EA, Ozawa M, Takemoto M, Nishiyama K, Ohi Y, Igarashi Y. Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-X(L): Gene expression. FEBS Lett 1997;407(1):97-100.
15. Wieder T, Geilen CC, Kolter T, Sadeghlar F, Sandhoff K, Brossmer R, Ihrig P, Perry D, Orfanos CE, Hannun YA. Bcl-2 antagonizes apoptotic cell death induced by two new ceramide analogues. FEBS Lett 1997;411(2-3):260-264.
16. Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Exp Cell Res 1997;234(2):442-451.
17. Kuo ML, Chen CW, Jee SH, Chuang SE, Cheng AL. Transforming growth factor beta1 attenuates ceramide-induced CPP32/Yama activation and apoptosis in human leukaemic HL-60 cells. Biochem J 1997;327(Pt 3):663-667.
18. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91(5):1700-1705.
19. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 1999;162(4):2049-2056.
20. Mengubas K, Riordan FA, Bravery CA, Lewin J, Owens DL, Mehta AB, Hoffbrand AV, Wickremasinghe RG. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism. Oncogene 1999;18(15):2499-2506.
21. 2-ceramide induced apoptosis in HL-60 cells. Life Sci 1999;65(16):1715-1723.
22. Muller-Wieprecht V, Riebeling C, Stooss A, Orfanos CE, Geilen CC. Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha and 1 alpha, 25-dihydroxyvitamin D(3). Arch Dermatol Res 2000;292(9):455-462.
23. Di Nardo A, Benassi L, Magnoni C, Cossarizza A. Seidenari S and Giannetti A. Ceramide 2 (N-acetyl sphingosine) is associated with reduction in Bcl-2 protein levels by Western blotting and with apoptosis in cultured human keratinocytes. Br J Dermatol 2000;143(3):491-497.
24. 2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: Significance for the molecular mechanism of Bcl-2 action. EMBO J 2001;20(11):2690-2701.
25. Park MT, Kang JA, Choi JA, Kang CM, Kim TH, Bae S, Kang S, Kim S, Choi WI, Cho CK, Chung HY, Lee YS, Lee SJ. Phytosphingosine induces apoptotic cell death via caspase-8 activation and Bax translocation in human cancer cells. Clin Cancer Res 2003;9(2):878-885.
26. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y, Iwai K, Tashima M, Uchiyama T, Okazaki T. Possible role of ceramide as an indicator of chemoresistance: Decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003;9(1):415-423.
27. Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ 2003;10(2):240-248.
28. Stoica BA, Movsesyan VA, Lea PM IV, Faden AI. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003;22(3):365-382.
29. Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004;91(5):1231-1243.
30. Kim HJ, Kang SY, Kim SJ, Kim SH, Kim TY. Potentiation of UVB-induced apoptosis by novel phytosphingosine derivative, tetraacetyl phytosphingosine in HaCaT cell and mouse skin. Apoptosis 2004;9(4):449-456.
31. Osawa Y, Uchinami H, Bielawski J, Schwabe RF, Hannun YA, Brenner DA. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-{alpha}. J Biol Chem 2005;280(30):27879-27887.
32. Nagahara Y, Shinomiya T, Kuroda S, Kaneko N, Nishio R, Ikekita M. Phytosphingosine induced mitochondria-involved apoptosis. Cancer Sci 2005;96(2):83-92.
33. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 2002;1585(2-3):193-201. Review.
34. Bieberich E. Integration of glycosphingolipid metabolism and cell-fate decisions in cancer and stem cells: Review and hypothesis. Glycoconj J 2004;216:315-327, Review.
35. Sauer B, Gonska H, Manggau M, Kim DS, Schraut C, Schafer-Korting M, Kleuser B. Sphingosine 1-phosphate is involved in cytoprotective actions of calcitriol in human fibroblasts and enhances the intracellular Bcl-2/Bax rheostat. Pharmazie 2005;60(4):298-304.
36. Lavieu G, Scarlatti F, Sala G, Levade T, Ghidoni R, Botti J, Codogno P. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? Autophagy 2007;3(1):45-47. Epub 2007 Jan 18.
37. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758(12):2016-2026, Review.
38. Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, Vadas MA. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006;118(10):2412-2420.
39. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. 2003; Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63:5962-5969.
40. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318(2):596-603.
41. Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, Brisbay S, McDonnell TJ. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 1997;237(1):101-109.
42. Bielawska A, Linardic CM, Hannun YA. Modulation of cell growth and differentiation by ceramide. FEBS Lett 1992;307(2):211-214.
43. Waterhouse NJ, Trapani JA. A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ 2003;10(7):853-855.
44. Ghosh SC, Auzenne E, Farquhar D, Klostergaard J. N,N-Dimethylsphingosine-Coumarin: Synthesis, chemical characterization and biological evaluation. Bioconjug Chem 2007; [Epub ahead of print].
45. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel S. N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: Modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 1998;37(37):12892-12898.
46. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B, Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005;65(24):11667-11675.
47. Donato NJ, Klostergaard J. Distinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cells. Exp Cell Res 2004;294(2):523-533.
48. Klostergaard J, Leroux ME, Auzenne E, Khodadadian M, Spohn W, Wu JY, Donato NJ. Hyperthermia enhances upstream TNF-dependent caspase activation, engages the intrinsic apoptotic pathway and overcomes apoptotic resistance in MCF-7 breast adenocarcinoma. J Cell Biochem 2006;98(2):356-369.
49. Dangel GR, Lang F, Lepple-Wienhues A. Effect of sphingosine on Ca2+ entry and mitochondrial potential of Jurkat T cells - interaction with Bcl2. Cell Physiol Biochem 2005;16(1-3):9-14.
50. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: Role of Bcl-2 expression. Oncogene 2005;24(1):178-187.
51. Oh JE, So KS, Lim SJ, Kim MY. Induction of apoptotic cell death by a ceramide analog in PC-3 prostate cancer cells. Arch Pharm Res 2006;29(12):1140-1146.
52. Nagahara Y, Shinomiya T, Kuroda S, Kaneko N, Nishio R, Ikekita M. Phytosphingosine induced mitochondria-involved apoptosis. Cancer Sci 2005;96(2):83-92.
53. Park MT, Kang JA, Choi JA, Kang CM, Kim TH, Bae S, Kang S, Kim S, Choi WI, Cho CK, Chung HY, Lee YS, Lee SJ. Phytosphingosine induces apoptotic cell death via caspase-8 activation and Bax translocation in human cancer cells. Clin Cancer Res 2003;9(2):878-885.
54. Park HW, Song JY, Kim KS, Han Y, Kim CW, Yi SY, Yun YS. Enhancement of radiosensitivity by combined ceramide and dimethylsphingosine treatment in lung cancer cells. Exp Mol Med 2004;36(5):411-419.
55. Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004;91(5):1231-1243.
56. Vendor's information.
57. Siskind LJ, Fluss S, Bui M, Colombini M. Sphingosine forms channels in membranes that differ greatly from those formed by Ceramide. J Bioenerg Biomembr 2005;37(4):227-236.
58. Gulley J, Dahut WL. Chemotherapy for prostate cancer: Finally an advance! Am J Ther 2004;11(4):288-294, Review.
59. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004;91(8):1425-1427.
60. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control 2004;11(6):364-373.
61. Beer TM. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005;96(4):508-513.
62. Augustin H, Hammerer PG, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol 2003;129(11):662-668.
63. Tulunay O, Orhan D, Baltaci S, Gogus C, Muftuoglu YZ. Prostatic ductal adenocarcinoma showing Bcl-2 expression. Int J Urol 2004;11(9):805-808.
64. Chi KN. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 2005;23(1):33-37.
65. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41(6):858-887.
66. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003;97(7):1630-1638.
67. Wu TT, Hsu YS, Wang JS, Lee YH, Huang JK. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 2003;170(1):78-81.
68. Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 2003;56(1):1-6.
69. Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ 2003;10(2):240-248.
70. Bencini S, Migaldi M, Castagnetti G, Pincelli C, Ferrari P, De Gaetani C, Trentini GP. Apoptosis in prostate carcinoma before and after neoadjuvant therapy with LH-RH analog. Ann NY Acad Sci 2003;1010:789-792.
71. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10(22):7721-7726.
72. Gleave M, Nelson C, Chi K. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Curr Drug Targets 2003;4(3):209-221.
73. Lai JC, Benimetskaya L, Santella RM, Wang Q, Miller PS, Stein CA. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther 2003;2(10):1031-1043.
74. Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A, Benimetskaya L. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004;10(9):3195-3206.
75. Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004;10(15):5048-5057.
76. Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N, Scher HI. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immunohistochem Mol Morphol 2005;13(1):6-13.
77. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435(7042); 677-681.
78. Shore GC, Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology (Am Soc Hematol Educ Program) 2005; 226-230.
79. Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 2006;49(3):1165-1181.
80. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004;12(5):955-965.
81. Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol 2003;7(2):117-138.
82. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004;9(6):691-704.
83. Inoue S, Snowden RT, Dyer MJ, Cohen GM. CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia 2004;18(5):948-952.
84. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55(3):178-194.
85. Dai Y, Dent P, Grant S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. Mol Pharmacol 2003;64(6):1402-1409.
86. Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 2004;18(11):1780-1788.